share_log

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product

《每日生物技術脈搏》:Neurocrine、Editas 候選人的美國食品藥品管理局孤兒藥標籤;BridgeBio 的 PRV 的出售;PolarityTE 產品的 RMAT 認證
Benzinga Real-time News ·  2022/05/13 10:43
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去24小時生物技術領域的熱門發展綜述:
Stocks In Focus
關注的股票
Switzerland Approves Moderna's COVID-19 Shot For Kids 6-11
瑞士批准Moderna為6-11歲兒童拍攝新冠肺炎
The Swiss drug regulatory authority has approved Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine for children ages 6-11. 
瑞士藥品監管機構已經批准了。Moderna中國(納斯達克:信使)6-11歲兒童新冠肺炎疫苗
The approval is for the vaccine's two-dose series of 50 micrograms per dose, Moderna added.
Moderna補充說,批准的是該疫苗的兩劑系列,每劑50微克。
Shares were up 6.72% at $138.92 Friday. 
該公司股價上週五上漲6.72%,至138.92美元。
Neurocrine's Huntington's Candidate Secures FDA Orphan Drug Tag
Neurocrine的亨廷頓候選人獲得FDA孤兒藥物標籤
The FDA has granted Orphan Drug Designation to Neurocrine Biosciences Inc's (NASDAQ:NBIX) valbenazine for Huntington's disease (HD). 
美國食品和藥物管理局已將孤兒藥物名稱授予美國Neurocrine Biosciences Inc.納斯達克:nbix)valbenazine治療亨廷頓病(HD)。
The treatment of chorea associated with...
與HD相關的...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論